|
[1]
|
Nissan, G.R., Kim, R., Cohen, J.M., et al. (2022) Reducing the Burden of Migraine: Safety and Efficacy of CGRP Pathway-Targeted Preventive Treatments. Journal of Clinical Medicine, 11, Article No. 4359. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Steiner, T.J., Stovner, L.J., Vos, T., et al. (2018) Migraine Is First Cause of Disability in under 50s: Will Health Politicians Now Take Notice? The Journal of Headache and Pain, 19, Article No. 17. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Olesen, J. (2018) Headache Classification Committee of the Inter-national Headache Society (IHS). The International Classification of Headache Disorders, 3rd Edition. Cephalalgia, 38, 1-211. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Alwhaibi, M., Balkhi, B. and Al Ruthia, Y. (2023) Anxie-ty and Depression and Health-Related Quality of Life among Adults with Migraine: A National Population-Based Study. Frontiers in Public Health, 11, Article ID: 1241800. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Lv, X., Xu, B., Tang, X., et al. (2023) The Relationship between Major Depression and Migraine: A Bidirectional Two-Sample Mendelian Randomization Study. Frontiers in Neurology, 14, Article ID: 1143060. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Waliszewska-Prosół, M., Nowakowska-Kotas, M., Cho-jdak-Łukasiewicz, J., et al. (2021) Migraine and Sleep—An Unexplained Association? International Journal of Molecu-lar Sciences, 22, Article No. 5539. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Blitshteyn, S. (2023) Dysautonomia, Hypermobility Spectrum Disor-ders and Mast Cell Activation Syndrome as Migraine Comorbidities. Current Neurology and Neuroscience Reports, 23, 769-776. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Burrowes, S.A.B., Goloubeva, O., Stafford, K., et al. (2023) Enhanced Mindfulness-Based Stress Reduction in Episodic Migraine-Effects on Sleep Quality, Anxiety, Stress, and De-pression: A Secondary Analysis of a Randomized Clinical Trial. Pain, 164, E120-E120. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Ferrari, M.D., Goadsby, P.J., Rami, B., et al. (2022) Mi-graine (Primer). Nature Reviews: Disease Primers, 8, Article No. 2. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Thuraiaiyah, J., Erritzøe-Jervild, M., Al-Khazali, H.M., et al. (2022) The Role of Cytokines in Migraine: A Systematic Review. Cephalalgia, 42, 1565-1588. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Obata, H. (2017) Analgesic Mechanisms of Antidepressants for Neuropathic Pain. International Journal of Molecular Sciences, 18, Article No. 2483. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Silberstein, S.D., Holland, S., Freitag, F., et al. (2012) Evidence-Based Guideline Update: Pharmacologic Treatment for Episodic Migraine Prevention in Adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology, 78, 1337-1345. [Google Scholar] [CrossRef]
|
|
[13]
|
Ozyalcin, S.N., Talu, G.K., Kiziltan, E., et al. (2005) The Efficacy and Safety of Venlafaxine in the Prophylaxis of Migraine. Headache: The Journal of Head and Face Pain, 45, 144-152. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Couch, J.R. (2011) Amitriptyline in the Prophylactic Treatment of Migraine and Chronic Daily Headache. Headache: The Journal of Head and Face Pain, 51, 33-51. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Kalita, J., Kumar, S., Singh, V.K., et al. (2021) A Ran-domized Controlled Trial of High Rate RTMS versus RTMS and Amitriptyline in Chronic Migraine. Pain Physician, 24, e733. [Google Scholar] [CrossRef]
|
|
[16]
|
Sherafat, A., Sahebnasagh, A., Rahmany, R., et al. (2022) The Preventive Effect of the Combination of Atorvastatin and Nortriptyline in Migraine-Type Headache: A Randomized, Triple-Blind, Placebo-Controlled Trial. Neurological Research, 44, 311-317. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Hedayat, M., Nazarbaghi, S., Heidari, M., et al. (2022) Ven-lafaxine Can Reduce the Migraine Attacks as Well as Amitriptyline: A Noninferiority Randomized Trial. Clinical Neu-rology and Neurosurgery, 214, Article ID: 107151. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
戎天艺, 何旻. 文拉法辛治疗前庭性偏头痛的疗效观察[J]. 现代药物与临床, 2021, 36(5): 916-920.
|
|
[19]
|
Miyahara, Y., Funahashi, H., Haruta-Tsukamoto, A., et al. (2021) Time Course of Effects of Venlafaxine on Migraine and Generalized Pruritus in a Patient with Depression. Clinical Case Re-ports, 9, e05088. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Kisler, L.B., Weissman-Fogel, I., Coghill, R.C., et al. (2019) Individualiza-tion of Migraine Prevention. The Clinical Journal of Pain, 35, 753-765. [Google Scholar] [CrossRef]
|
|
[21]
|
雷爱弟. 度洛西汀治疗前庭性偏头痛的临床疗效[J]. 临床合理用药杂志, 2021, 14(30): 79-81.
|
|
[22]
|
Foong, A.L., Patel, T., Kellar, J., et al. (2018) The Scoop on Serotonin Syndrome. Canadian Pharmacists Journal, 151, 233-239. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Meng, Y. and Yuen, J. (2023) Onset of Transient Sadness Following the Concomitant Use of a Triptan and Selective Serotonin Reuptake Inhibitor/Serotonin Norepinephrine Reuptake Inhibitors Therapy: A Case Report. Journal of Pharmacy Prac-tice, 36, 705-710. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Deligianni, C.I., Sacco, S., Ekizoglu, E., et al. (2023) European Headache Federation (EHF) Critical Re-Appraisal and Meta-Analysis of Oral Drugs in Migraine Pre-vention—Part 2: Flunarizine. The Journal of Headache and Pain, 24, Article No. 128. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Burch, R. (2019) Antidepressants for Preventive Treatment of Migraine. Current Treatment Options in Neurology, 21, 1-12. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Sebastianelli, G., Casillo, F., Di, Renzo, A., et al. (2023) Effects of Botulinum Toxin Type A on the Nociceptive and Lemniscal Somatosensory Systems in Chronic Migraine: An Elec-trophysiological Study. Toxins, 15, Article No. 76. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Finzi, E. (2023) Botulinum Toxin Treatment for Depression: A New Paradigm for Psychiatry. Toxins, 15, Article No. 336. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Engel, E.R. and Ham, J.A. (2023) Amelioration of Trichotillomania with OnabotulinumtoxinA for Chronic Migraine. BMJ Case Reports, 16, e254006. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Turkel, C.C., Aurora, S., Diener, H.C., et al. (2023) Treatment of Chronic Migraine with Botox (OnabotulinumtoxinA): Development, Insights, and Impact. Medicine, 102, e32600. [Google Scholar] [CrossRef]
|
|
[30]
|
Stovner, L.J., Hagen, K., Tronvik, E., et al. (2022) FollowTheSutures: Piloting a New Way to Administer Onabotulinumtoxin A for Chronic Migraine. Cephalalgia, 42, 590-597. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Blumenfeld, A.M., Patel, A.T., Turner, I.M., et al. (2020) Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of Onabotulinumtoxina and Topiramate for Headache Prevention in Adults with Chronic Migraine. Journal of Primary Care & Community Health, 11, 2150132720959936. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Tereshko, Y., Lettieri, C., Belgrado, E., et al. (2023) Efficacy and Safety of Two Different Botulinum Toxin Type A Dilutions in Chronic Migraineurs. Toxicon, 227, Article ID: 107096. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Zhu, J., Chen, J. and Zhang, K. (2022) Clinical Effect of Flunarizine Combined with Duloxetine in the Treatment of Chronic Migraine Comorbidity of Depression and Anxiety Disorder. Brain and Behavior, 12, e2689. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Wang, Y., Yang, X., Ji, X., et al. (2023) Clinical Efficacy of Escitalopram Combined with Botulinum Toxin A in Patients with Generalized Anxiety Disorder and Comorbid Headache. Psycho-pharmacology, 240, 2061-2070. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Lee, A., Abouzari, M., Akbarpour, M., et al. (2023) A Proposed Association between Subjective Nonpulsatile Tinnitus and Migraine. World Journal of Otorhinolaryngology—Head and Neck Surgery, 9, 107-114. [Google Scholar] [CrossRef] [PubMed]
|